Shan, Joseph S.,Kallinteris, Nikoletta L.,Tang, Min,Dorr, Andrew F.
申请号：
AU2018249493
公开号：
AU2018249493A1
申请日:
2018.04.02
申请国别(地区):
AU
年份:
2019
代理人:
摘要：
Disclosed are methods and kits for treating patients, particularly cancer patients, using bavituximab in combination therapies with immuno-oncology (IO) agents such as checkpoint inhibitor antibodies. The methods and kits are based on the surprising finding that human patients treated with bavituximab and checkpoint inhibitor antibodies have a statistically significant prolonged survival in controlled studies.
